Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAAR1 | Q96RJ0 | 4/20 | 0.41 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.41 |
| ▸ | MAOA | P21397 | 1/20 | 0.41 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.41 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.41 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.41 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.41 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.41 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.41 |
| ▸ | HTR2A | P28223 | 1/20 | 0.40 |
| ▸ | HTR2C | P28335 | 1/20 | 0.40 |
| ▸ | HTR2B | P41595 | 1/20 | 0.40 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.40 |
| ▸ | PNMT | P11086 | 1/20 | 0.40 |
| ▸ | SLC7A5 | Q01650 | 4/20 | 0.38 |
| ▸ | F11 | P03951 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5261400 | 0.81 | TAAR1 (0.49) | TAAR1SLC6A2MAOASLC6A4SLC6A3 | |
| SCHEMBL5489314 | 0.81 | TAAR1 (0.49) | TAAR1SLC6A2MAOASLC6A4SLC6A3 | |
| SCHEMBL5311932 | 0.81 | TAAR1 (0.49) | TAAR1SLC6A2MAOASLC6A4SLC6A3 | |
| SCHEMBL5914073 | 0.81 | TAAR1 (0.49) | TAAR1SLC6A2MAOASLC6A4SLC6A3 | |
| SCHEMBL5205938 | 0.80 | OPRK1 (0.44) | SLC6A3OPRK1 | |
| SCHEMBL5206391 | 0.80 | OPRK1 (0.44) | SLC6A3OPRK1 | |
| SCHEMBL5948117 | 0.74 | NPC1 (0.51) | TAAR1SIGMAR1SLC7A5 | |
| SCHEMBL4001568 | 0.74 | NPC1 (0.51) | TAAR1SIGMAR1SLC7A5 | |
| SCHEMBL5914427 | 0.74 | NPC1 (0.51) | TAAR1SIGMAR1SLC7A5 | |
| SCHEMBL5914431 | 0.74 | NPC1 (0.51) | TAAR1SIGMAR1SLC7A5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070054916-A1 | Aryl nitrogen-containing bicyclic compounds and methods of use | AMGEN INC. | 2007-03-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070054916-A1 | Aryl nitrogen-containing bicyclic compounds and methods of use | MAP3K1, MAP3K5, MAP3K2 | TAAR1 1307/4885SLC6A2 4536/4885MAOA 995/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.